Caronna, Edoardo http://orcid.org/0000-0001-5525-0267
Gallardo, Victor José http://orcid.org/0000-0002-3042-2007
Alpuente, Alicia http://orcid.org/0000-0001-5296-9401
Torres-Ferrus, Marta http://orcid.org/0000-0003-2856-4134
Pozo-Rosich, Patricia http://orcid.org/0000-0003-0796-4702
Article History
Received: 27 April 2021
Revised: 11 July 2021
Accepted: 13 July 2021
First Online: 20 July 2021
Declarations
:
: There are no conflicts of interest in regard to this manuscript. Dr Caronna has received honoraria from Lundbeck, Novartis, Chiesi. Mr Gallardo reports no disclosures. Dr Alpuente has received honoraria from Allergan plc, Novartis, Chiesi. Dr Torres-Ferrus has received honoraria from Allergan plc, Novartis, Chiesi. Dr Pozo-Rosich has received honoraria as a consultant and speaker for: Allergan-AbbVie, Almirall, Biohaven, Chiesi, Eli Lilly, Medscape, Neurodiem, Novartis and Teva. Her research group has received research grants from Novartis; has received funding for clinical trials from Alder, Amgen, Electrocore, Eli Lilly, Novartis, Teva. She is a trustee member of the board of the International Headache Society and the Council of the European Headache Federation. She is in the editorial board of Revista de Neurologia. She is an editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology and and advisor for The Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of ExternalRef removed. PP-R does not own stocks from any pharmaceutical company.
: The study was approved by the Vall d’Hebron Ethics Committee (PR(AG)646/2020).
: All patients gave an informed consent for the analysis of patients’ data which was collected according to Spanish regulation on clinical trials. All patients consented to publication of anonymous individual data.